February 19, 2024
Cyclarity Therapeutics is developing an affordable, plaque-busting small molecule that may be the cure for the world's number one killer: cardiovascular disease. With human trials planned for this year, we decided that it was time to catch up with Cyclarity and its CEO of Scientific Affairs, Dr. Matthew O’Connor, to see how things were going....
February 28, 2023
Cyclarity Therapeutics is striving to make powerful treatments for cardiovascular disease and, most importantly, make them accessible and affordable. Their cutting-edge cyclodextrin technology targets atherosclerosis, aiming to eliminate the buildup of non-degradable oxidized cholesterol that gets stuck inside cells in the arterial walls. The company has made great progress towards launching its cyclodextrin drug for...
September 10, 2021
Underdog Pharmaceuticals (Now called Cyclarity Therapeautics) has just issued a press release announcing that UDP-003, a compound being studied for its effectiveness against oxidized cholesterol, has been given an Innovation Passport under the UK's Innovative Licensing and Access Pathway program. This is similar to the Fast Track designation given by the FDA in the United...
January 09, 2020
There are lots of exciting companies working in the aging field, and it's a great time to tell you about three of the more interesting ones. Most of these companies are a while away from human trials yet, but their innovations could possibly be truly game changing. Underdog Pharma Underdog Pharmaceuticals is a spin-off company...
December 04, 2019
For the December edition of the Journal Club hosted by Dr. Oliver Medvedik, we are joined by Dr. Matthew O' Connor (Oki) formerly of SENS Research Foundation and now the head researcher at Underdog Pharma, a spun-off biotech company that is developing research conducted at SENS into a hopefully viable solution for heart disease. Dr....